Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation
- PMID: 29761483
- DOI: 10.1111/bjd.16734
Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation
Abstract
Background: Atopic dermatitis is a systemic disorder characterized by abnormal barrier function across multiple organ sites. Causes of epidermal barrier breakdown are complex and driven by a combination of structural, genetic, environmental and immunological factors. In addition, alteration in microflora diversity can influence disease severity, duration, and response to treatment. Clinically, atopic dermatitis can progress from skin disease to food allergy, allergic rhinitis, and later asthma, a phenomenon commonly known as the atopic march. The mechanism by which atopic dermatitis progresses towards gastrointestinal or airway disease remains to be elucidated.
Objectives: This review addresses how epithelial dysfunction linking microbiome alteration and immune dysregulation can predispose to the development of the atopic march.
Methods: A literature search was conducted using the PubMed database for relevant articles with the keywords 'atopic dermatitis', 'epithelial barrier', 'skin', 'gut', 'lung', 'microbiome' and 'immune dysregulation'.
Results: Initial disruption in the skin epidermal barrier permits allergen sensitization and colonization by pathogens. This induces a T helper 2 inflammatory response and a thymic stromal lymphopoietin-mediated pathway that further promotes barrier breakdown at distant sites, including the intestinal and respiratory tract.
Conclusions: As there are no immediate cures for food allergy or asthma, early intervention aimed at protecting the skin barrier and effective control of local and systemic inflammation may improve long-term outcomes and reduce allergen sensitization in the airway and gut.
© 2018 British Association of Dermatologists.
Similar articles
-
The origins of allergy from a systems approach.Ann Allergy Asthma Immunol. 2020 Nov;125(5):507-516. doi: 10.1016/j.anai.2020.07.013. Epub 2020 Jul 21. Ann Allergy Asthma Immunol. 2020. PMID: 32702411 Review.
-
Influences on allergic mechanisms through gut, lung, and skin microbiome exposures.J Clin Invest. 2019 Feb 25;129(4):1483-1492. doi: 10.1172/JCI124610. eCollection 2019 Feb 25. J Clin Invest. 2019. PMID: 30830878 Free PMC article. Review.
-
The atopic march and atopic multimorbidity: Many trajectories, many pathways.J Allergy Clin Immunol. 2019 Jan;143(1):46-55. doi: 10.1016/j.jaci.2018.11.006. Epub 2018 Nov 17. J Allergy Clin Immunol. 2019. PMID: 30458183 Review.
-
Outstanding animal studies in allergy II. From atopic barrier and microbiome to allergen-specific immunotherapy.Curr Opin Allergy Clin Immunol. 2017 Jun;17(3):180-187. doi: 10.1097/ACI.0000000000000364. Curr Opin Allergy Clin Immunol. 2017. PMID: 28375932 Free PMC article. Review.
-
The ins and outs of an 'outside-in' view of allergies: atopic dermatitis and allergy prevention.Curr Opin Pediatr. 2018 Aug;30(4):576-581. doi: 10.1097/MOP.0000000000000646. Curr Opin Pediatr. 2018. PMID: 29750772 Review.
Cited by
-
The innate immune perspective of autoimmune and autoinflammatory conditions.Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi1-vi8. doi: 10.1093/rheumatology/kez387. Rheumatology (Oxford). 2019. PMID: 31769855 Free PMC article. Review.
-
Salidroside alleviates atopic dermatitis-like responses by inhibiting MAPKs and NF-κB signaling pathways.Arch Dermatol Res. 2025 Apr 1;317(1):666. doi: 10.1007/s00403-025-04091-4. Arch Dermatol Res. 2025. PMID: 40167805
-
Assessment of Mucosa-Associated Epithelial Chemokine, Thymus-Expressed Chemokine, Periostin and Zonulin Levels in Infants With Atopic Dermatitis.Indian J Dermatol. 2022 May-Jun;67(3):312. doi: 10.4103/ijd.ijd_834_21. Indian J Dermatol. 2022. PMID: 36386107 Free PMC article.
-
Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial.Pediatr Allergy Immunol. 2022 Aug;33(8):e13836. doi: 10.1111/pai.13836. Pediatr Allergy Immunol. 2022. PMID: 36003050 Free PMC article. Clinical Trial.
-
Microbiome Composition and Its Impact on the Development of Allergic Diseases.Front Immunol. 2020 Apr 23;11:700. doi: 10.3389/fimmu.2020.00700. eCollection 2020. Front Immunol. 2020. PMID: 32391012 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials